Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alternative RNA Splicing02:18

Alternative RNA Splicing

21.0K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
21.0K
RNA Splicing01:32

RNA Splicing

56.0K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
56.0K
Pre-mRNA Processing: RNA Splicing01:36

Pre-mRNA Processing: RNA Splicing

5.2K
5.2K
Chromatin Structure and RNA Splicing02:41

Chromatin Structure and RNA Splicing

2.7K
2.7K
RNA Interference01:23

RNA Interference

25.9K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
25.9K
MicroRNAs01:22

MicroRNAs

3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Artificial intelligence in urology: A review of United States Food and Drug Administration-cleared devices.

BJU international·2026
Same author

Proton FLASH preserves neurocognition across delivery techniques: implications for clinical translation in pediatric brain tumors.

bioRxiv : the preprint server for biology·2026
Same author

Publisher Correction: Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma.

Nature cancer·2026
Same author

Publisher Correction: Single-cell epigenetic and transcriptomic states across the continuum of monoclonal B cell lymphocytosis to chronic lymphocytic leukemia.

Genome biology·2026
Same author

Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma.

Nature cancer·2026
Same author

Tempered Optimism: Advances in the Precision Medicine Era for Pediatric Low-Grade Glioma.

Neuro-oncology·2026

Related Experiment Video

Updated: Jun 4, 2025

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

13.6K

CoREST Complex Inhibition Alters RNA Splicing to Promote Neoantigen Expression and Enhance Tumor Immunity.

Robert J Fisher, Kihyun Park, Kwangwoon Lee

    Biorxiv : the Preprint Server for Biology
    |December 23, 2024
    PubMed
    Summary
    This summary is machine-generated.

    The CoREST repressor complex interacts with RNA splicing, and its inhibitor, corin, alters splicing in cancer. This generates neoantigens, enhancing anti-cancer immunity and T cell responses in tumors.

    More Related Videos

    Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
    07:23

    Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

    Published on: May 30, 2025

    73
    Author Spotlight: Exploring Strategies for Successful Immune Response Against Tumors
    05:58

    Author Spotlight: Exploring Strategies for Successful Immune Response Against Tumors

    Published on: August 16, 2024

    2.7K

    Related Experiment Videos

    Last Updated: Jun 4, 2025

    Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
    09:58

    Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

    Published on: December 9, 2016

    13.6K
    Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
    07:23

    Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

    Published on: May 30, 2025

    73
    Author Spotlight: Exploring Strategies for Successful Immune Response Against Tumors
    05:58

    Author Spotlight: Exploring Strategies for Successful Immune Response Against Tumors

    Published on: August 16, 2024

    2.7K

    Area of Science:

    • Epigenetics
    • Transcriptional Regulation
    • Cancer Immunology

    Background:

    • Epigenetic complexes regulate gene expression and interact with RNA splicing machinery.
    • The functional consequences of these interactions in cancer are not well understood.

    Purpose of the Study:

    • To investigate the interactions between the CoREST repressor complex and RNA splicing factors.
    • To determine the functional consequences of these interactions in tumorigenesis and cancer immunity.

    Main Methods:

    • Mass spectrometry
    • In vivo binding assays
    • Cryo-electron microscopy (cryo-EM)
    • Predictive machine learning models
    • MHC IP-MS

    Main Results:

    • Identified direct interactions between the CoREST complex and RNA splicing factors.
    • Corin, a CoREST inhibitor, perturbs these interactions, causing widespread RNA splicing changes in malignancies.
    • Discovered thousands of corin-induced neopeptides from unannotated splice sites, generating immunogenic splice-neoantigens.
    • Corin reactivated immune checkpoint blockade response and expanded cytotoxic T cells in an immune-cold melanoma model.

    Conclusions:

    • CoREST complex inhibition is a novel therapeutic strategy in cancer.
    • Corin treatment generates tumor-associated neoantigens, enhancing cancer immunogenicity.
    • This approach promotes T cell-mediated immunity, particularly in immune-cold tumors.